-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 F3WLA0K28qkbWxARCzIitbqy1SwI1OWPdXVcxaDgIPDA1VKPQoEdQs4t9+iziAFs
 zX07rTKou8M423bngghCpA==

<SEC-DOCUMENT>0000927946-03-000125.txt : 20030529
<SEC-HEADER>0000927946-03-000125.hdr.sgml : 20030529
<ACCEPTANCE-DATETIME>20030529145937
ACCESSION NUMBER:		0000927946-03-000125
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20030526
ITEM INFORMATION:		Other events
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20030529

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		03723360

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bas8k.htm
<DESCRIPTION>BIOANALYTICAL SYSTEMS, INC. - FORM 8-K
<TEXT>
<HTML>
<HEAD>
<Title>Bioanalytical Systems, Inc. - Form 8K</title></head>
<BODY>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<b>UNITED STATES</b><br>
<b>SECURITIES AND EXCHANGE COMMISSION</b></FONT><br>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<b>Washington, D.C. 20549</b></font></P>
<br>

<hr width=30% noshade>

<p align=center><FONT FACE="Times New Roman, Times, Serif" size=4>
<b>FORM 8-K</b><BR><br>
<B>CURRENT REPORT</B><BR><br>
<b><small>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</small></b>
</font></p>
<hr width=30% noshade>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
Date of Report (Date of earliest event reported):&nbsp;&nbsp;<b>May 26, 2003</b>
</font></p>
<br>
<br>
<br>
<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=4>
<b><u>BIOANALYTICAL SYSTEMS, INC.</u></b><br>
<small><small><small>(Exact name of registrant as specified in its charter)</small></small></small>
</font></P>

<table width=95% border=0>
<tr valign=bottom><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<u><B>Indiana</B></u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
<B>0-23357</B></u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
<B>35-1345024</B></u></font></td></TR>

<TR VALIGN=TOP>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(State or other jurisdiction of<br>incorporation or organization)</font></TD>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Commission File Number)</font></td>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(IRS Employer Identification No.)</font></td></TR>
<tr><TD><br></TD></tr>

<TR VALIGN=bottom><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<B>2701 Kent Avenue</B><br>
<u><B>West Lafayette, IN</B></u></font></TD>
<TD></TD> <td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><br>
<u><B>47906-1382</B></u></font></td></TR>
<TR VALIGN=top><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Address of principal executive offices)</font></TD><TD>
</TD><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Zip Code)</font></td></TR>
<tr><TD></TD></tr>
<TR VALIGN=top><TD> </TD><TD align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<u><B>(765) 463-4527</B></u></font></TD></TR>
<TR VALIGN=top><TD> </TD><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Registrant's telephone number, including area code)</font></TD></TR>
</TABLE>

<PAGE>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
Item 5.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
     On May 28, 2003, Bioanalytical Systems, Inc. (the "Company") and
PharmaKinetics Laboratories, Inc. ("PKLB") issued a joint press release
announcing the purchase by the Company of 4,992,300 shares of common stock of
PKLB through the conversion by the Company of a portion of the balance
outstanding under the Amended and Restated Secured Convertible Revolving Note
dated April 30, 2003 issued by PKLB to BASi. The conversion was effective as of
May 26, 2003. A copy of the press release is filed herewith as Exhibit 99.1 and
incorporated herein by reference.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
Item 7.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following exhibits are filed as a part of this report:</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Exhibits</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Press release dated May 28, 2003.</font></P>

<PAGE>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
<B>SIGNATURES</B></font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></P>

<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE width=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
Date:&nbsp;&nbsp;&nbsp;&nbsp;May 29, 2003</font></TD>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>BIOANALYTICAL SYSTEMS, INC.</U><BR>
(Registrant)<BR>
<BR>
<BR>
<BR>
By:&nbsp;&nbsp;/s/&nbsp;&nbsp;Peter T. Kissinger<hr>
Peter T. Kissinger, Ph.D.<BR>
President and Chief Executive Officer<BR>
</FONT></TD>
</TR>
</TABLE>
<BR>

<PAGE>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
<B><u>Exhibit Index</u></B></font></P>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit Header" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=BOTTOM>
<TH WIDTH=20%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item Number<BR>
assigned in<BR>
<U>Regulation S-K</U>
</FONT></TH>
<TH WIDTH=15%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit</U></FONT></TH>
<TH WIDTH=65%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Description of Exhibits</U>
</FONT></TH>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
99</FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
(99.1)</FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Press release dated May 28, 2003.</FONT></DIV></TD>
</TR>
</TABLE>
<BR>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit991.htm
<DESCRIPTION>PRESS RELEASE DATED MAY 27, 2003
<TEXT>
<HTML>
<HEAD>
<TITLE>Bioanalytical Systems, Inc. - Exhibit 99.1</TITLE>
</HEAD>
<BODY>

<P align=right>
<FONT FACE="Times New Roman, Times, Serif" SIZE="2">
FOR MORE INFORMATION:&nbsp;&nbsp;&nbsp;&nbsp;Michael P. Silvon<BR>
765.497.5831<BR> </FONT>
<FONT FACE="Times New Roman, Times, Serif" SIZE="2" COLOR="#0000FF">
<U>silvon@bionalytical.com </U></FONT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><BR>
OR<BR>
Jim Wilkinson<BR>
410.385.4500<BR>
<I>jwilkinson@pharmakinetics.com</I></FONT></P>
<BR>


<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     WEST LAFAYETTE, Ind., May 28, 2003 &#151; Bioanalytical Systems, Inc. (Nasdaq:
BASI) and PharmaKinetics Laboratories, Inc. (OTCBB:PKLB) today jointly announced
that BASi has purchased 4,992,300 shares of the $.005 par value common stock of
PKLB through the conversion by BASi of a portion of the balance outstanding
under the Amended and Restated Secured Convertible Revolving Note dated April
30, 2003 issued by PKLB to BASi. These shares of common stock represent
approximately 67% of the total issued and outstanding shares of common stock of
PKLB.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     On June 20, 2002, BASi and PKLB announced that they had entered into a
definitive agreement for the acquisition of PKLB by BASi through the merger of
PKLB with a wholly-owned subsidiary of BASi. The parties continue to work toward
the closing of this acquisition and are optimistic that the closing will occur
within the next 60 days, although the closing of the merger is subject to
numerous conditions, and there can be no guarantee that the closing will occur
as anticipated or at all.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     BASi has filed with the Securities and Exchange Commission a preliminary
Registration Statement on Form S-4 relating to the proposed merger. The Form S-4
contains a preliminary prospectus of BASi relating to the shares to be issued in
the merger and a preliminary proxy statement of PKLB relating to the special
meeting of shareholders of PKLB at which the merger will be considered and voted
upon by its shareholders. Investors and security holders are urged to read the
definitive proxy statement/prospectus when it becomes available and any other
relevant documents filed with the Securities and Exchange Commission before
making any investment decisions. Investors and security holders may obtain a
free copy of the definitive proxy statement/final prospectus (when it becomes
available) and other documents filed by BASi and PKLB with the Securities and
Exchange Commission at the Commission's website at www.sec.gov. The definitive
proxy statement/final prospectus and other documents filed by PKLB with the
Securities and Exchange Commission may also be obtained free of charge from PKLB
by requesting a copy in writing from PharmaKinetics Laboratories, Inc., 302 W.
Fayette Street, Baltimore, Maryland 21201, Attention: Chief Financial Officer,
or by telephone at (410) 385-4500.
</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     In business for nearly 30 years, BASi is a pharmaceutical development
company who provides contract research services and analytical systems to the
world&#145;s leading pharmaceutical, drug development and medical device companies.
See www.bioanalytical.com for more about BASi. PharmaKinetics Laboratories, Inc.
is a contract research organization providing a range of clinical research and
development services to the worldwide pharmaceutical and biotechnology
industries in the development of prescription and non-prescription drug
products. Visit www.pharmakinetics.com for more about PKLB.</font></P>
<BR>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
     <I>This release contains forward-looking statements that are subject to
risks and uncertainties including, but not limited to, risks and uncertainties
related to the development of products and services, changes in technology,
industry standards and regulatory standards, and various market and operating
risks detailed in the company&#145;s filings with the Securities and Exchange
Commission.</I>
</font></P>
<BR>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
# # # # #</font></P>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
